NYRADA INC. - News & Media

3.85%

27.0¢

Market Cap $64.47M

Healthcare Biotechnology

Nyrada Inc is an Australia-based drug development company. The Company focuses on... Nyrada Inc is an Australia-based drug development company. The Company focuses on development of small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. Its drug development programs include a proprotein convertase subtilisin/kexin type nine (PCSK9) inhibitor for the treatment of high blood low-density lipoprotein (LDL)-cholesterol levels in patients poorly responsive to or unable to take statin drugs. It develops a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury. The Company also develops a drug to treat pain associated with peripheral nerve damage and autoimmune diseases such as psoriasis.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 27.0¢		Change 0.010(3.85%)		Mkt cap ! $64.47M

Open	High	Low	Value	Volume
26.5¢	27.0¢	25.5¢	$76.90K	292.3K

Buyers (Bids)

No.	Vol.	Price($)
1	2000	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	33900	1

View Market Depth

No.	Vol.	Price($)
1	2000	0.260
7	116388	0.250
2	83000	0.245
1	4166	0.240
1	4242	0.235

Price($)	Vol.	No.
0.270	33900	1
0.280	295699	2
0.285	55144	1
0.290	29778	2
0.300	20000	1

Last trade - 16.10pm 04/09/2025 (20 minute delay)


Last 26.5¢		Change 0.010 ( 3.92 %)
Open	High	Low	Volume
26.0¢	26.5¢	25.5¢	53208
Last updated 14.27pm 04/09/2025 ?

NYR (ASX) Chart

NYRADA INC. - News & Media

Articles & Videos

Nyrada pushes through to third cohort in Phase 1 trial for NYR-BI03

Study finds Nyrada's lead drug can prevent secondary brain injury

Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Nyrada (ASX:NYR) launches in vitro studies for brain injury program

Buyers (Bids)

Sellers (Offers)

Top Stories